Artelo Biosciences Files Patent on Use of Fatty Acid Binding Protein 5 Inhibitors for Treating Psychological Disorders
21 oct. 2020 08h30 HE
|
Artelo Biosciences
LA JOLLA, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended...
Artelo Biosciences, Inc. Announces Closing of $7.6 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option
14 oct. 2020 16h05 HE
|
Artelo Biosciences
LA JOLLA, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended...
Artelo Biosciences, Inc. Announces Pricing of $6.6 Million Upsized Underwritten Public Offering
09 oct. 2020 08h30 HE
|
Artelo Biosciences
LA JOLLA, Calif., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended...
Artelo Biosciences Receives Ethics Approval to Commence its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for the Treatment of Cancer-Related Anorexia
29 sept. 2020 08h00 HE
|
Artelo Biosciences
LA JOLLA, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the...
Artelo Biosciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15th
11 sept. 2020 09h00 HE
|
Artelo Biosciences
LA JOLLA, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid...
Artelo Biosciences to Participate in Two Keynote Panels at 3rd Annual International Cannabinoid Derived Pharmaceutical Summit
10 sept. 2020 09h15 HE
|
Artelo Biosciences
LA JOLLA, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid...
Artelo Biosciences Reports Third Quarter Fiscal Year 2020 Financial Results and Provides Business Update
14 juil. 2020 09h25 HE
|
Artelo Biosciences
LA JOLLA, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the...
Artelo Biosciences Expands Stony Brook Commercial License Agreement for FABP5 Platform for Development of Lead Cancer, Pain and Inflammation Compounds
29 juin 2020 08h30 HE
|
Artelo Biosciences
LA JOLLA, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the...
Artelo Biosciences to Participate in BIO Digital and The Investor Summit Conferences
03 juin 2020 09h30 HE
|
Artelo Biosciences
LA JOLLA, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid...
Artelo Biosciences Awarded Composition of Matter Patent for Novel CBD Cocrystal
12 mai 2020 09h30 HE
|
Artelo Biosciences
LA JOLLA, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing proprietary therapeutics that target the...